Associated with atopobium vaginae bacterial vaginosis: modern principles of diagnosis and therapy
Keywords:bacterial vaginosis, metronidazole, hexicon, Atopobium vaginae, clindamycin
Molecular biology techniques have shown that not all vaginal biotope microorganisms have been identified previously, which may play a role in the development of bacterial vaginosis. One of the previously undetectable by culture methods for diagnosis of vaginal microbial biotope is Atopobium vaginae.
5-nitroimidazoles drugs and clindamycin are currently used in the bacterial vaginosis treatment according to the current national and international recommendations. Studies showed that A. vaginae often resistant to metronidazole, being sensitive to only one of the recommended drugs clindamycin.
The study of efficacy and safety of the hexicon drug (vaginal suppositories) in treatment optimization of bacterial vaginosis that associated with A. vaginae was performed, compared with the efficacy and safety of traditional therapy (metronidazole, clindamycin).
The study included 60 women who were randomized in 3 groups according to treatment: in I group were 20 patients who underwent therapy with metronidazole gel 0.75%; group II include 20 patients who used clindamycin cream 2%; group III include 20 patients who underwent hexicon treatment.
Therapy effectiveness evaluated with clinical and laboratory examination, including assessment of the bacterial vaginosis symptoms according to Amsel’s criteria, evaluation of lactobacilli component of the vaginal microflora and A. vaginae identification.
Clinical and laboratory efficacy for vaginal suppositories hexicon in the treatment of bacterial vaginosis associated with A. vaginae was 95%, which is comparable to the drug of choice clindamycin (95%) and exceeded for metronidazole (80%). A. vaginae eradication therapy with hexicon was comparable with clindamycin (95 and 95% respectively) and significantly higher than for metronidazole (95 and 65%). The normal rate of vaginal lactobacilli microbiocenosis after treatment with hexicon were observed in 70% of patients, after clindamycin treatment – in 40%, and after metronidazole treatment – in 15% of patients. Hexicon had high safety and tolerability.
How to Cite
Copyright (c) 2016 М. Р. Рахматулина, К. И. Плахова
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.